PGGM Investments entered a position in
Danaher Co., purchasing $459,000 worth of shares. Meanwhile, recent movements in
Danaher Corp stock show fluctuations and mixed performance against the market. The company's
CEO Rainer Blair and
CFO Matthew Mcgrew recently sold a considerable number of their shares. Hedge Funds currently show bullish sentiments regarding the
scientific instruments stock, considering it as an under-the-radar compounding machine. The company released their Q2 2024 Earnings Call Transcript, with reports of
biotechnology sales dipping year over year. Brokerages recommend a moderate buy for Danaher with a target price set at $276.88. The firm's stock performs well amid market challenges, with some citing its
strategic SWOT insights contributing to its performance. Several noted investors, including
Cooper Investors and
Cetera Advisors LLC, made significant moves involving Danaher stock. Analysts highlight the company's
business strength amidst headwinds and its potential as a good medium-term bet. The company finally ended on a high note, with its Q2 2024 Earnings beating estimates and its stock surpassing revenue estimates.
Danaher Corporation DHR News Analytics from Wed, 11 Oct 2023 11:11:21 GMT to Sun, 04 Aug 2024 13:14:46 GMT -
Rating 8
- Innovation 4
- Information 6
- Rumor -2
